By far the two most common prostate diseases are prostatitis and benign hyperplasia (BPH). Prostatitis can be complicated by BPH or accompanied by periodic exacerbations. Drug therapy is an important component in the overall treatment of prostate disease. In addition, treatment often ends in defeat due to improper therapy, missed medications and, when the condition is resolved, neglect of the disease.
Thus, 20-30% of patients are dissatisfied with their treatment, do not feel a decrease in symptoms of urinary disorders and an improvement in quality of life. Most likely, this is due to an incorrect assessment of lower urinary tract function in men with BPH and, therefore, inadequate treatment options.
As you know, prostatitis is acute and chronic (CP), bacterial and bacterial.
Prostatitis in%
- acute bacterial prostatitis - 5-10%;
- chronic bacterial prostatitis - 6-10%;
- Chronic abacterial prostatitis - 80-90%, including prostatodynia - 20-30%.
The most common is chronic abacterial prostatitis, which must be controlled and prevented from getting worse with and without BPH.
The main drugs for the treatment of BPH and chronic prostatitis:
- 5a-reductase inhibitors (finasteride, dutasteride);
- a-blockers (doxazosin, tamsulosin);
- phytotherapy (sabal palm extract);
- antibiotics;
- amino acid complexes;
- animal organ extract (prostate extract);
- entomotherapy drugs (products derived from insects).
At the same time, in 13-30% of the effects of the use of a-blockers do not occur within 3 months of treatment-further therapy with drugs of this group is not recommended.
When prescribing finasteride, doctors should be prepared to know that the most significant side effects of this drug: impotence, decreased libido, decreased ejaculatory volume can lead to the intake of the drug itself by the patient.
Treatment of BPH and prostatitis is an important urological problem and cannot be completely solved.
Frequent CP irritation in the absence of indications for surgery on the prostate gland forces doctors to use additional methods in drug treatment. Often, the presence of CP concomitantly exacerbates the course of BPH, because inflammation in 80% of cases is in the prostate gland with benign hyperplasia.
Modern medicine gives us new opportunities for the treatment of CP and BPH and the prevention of deterioration.